中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (5): 471-475.doi: 10.35541/cjd.20210389
张元文1 孙从乾2 潘文东1
收稿日期:2021-05-17
修回日期:2022-07-20
发布日期:2024-04-30
通讯作者:
潘文东
E-mail:xsjl926yy@163.com
Zhang Yuanwen1, Sun Congqian2, Pan Wendong1
Received:2021-05-17
Revised:2022-07-20
Published:2024-04-30
Contact:
Pan Wendong
E-mail:xsjl926yy@163.com
摘要： 【摘要】 近年来，肉毒毒素被用于应对许多皮肤疾病和问题。本文回顾和分析肉毒毒素在皮肤科的超适应证临床应用，主要包括面部潮红、雷诺现象、带状疱疹后神经痛、银屑病等，为这些皮肤问题的治疗提供新的手段和思路。
张元文 孙从乾 潘文东. 肉毒毒素在皮肤科的超适应证临床应用[J]. 中华皮肤科杂志, 2024,57(5):471-475. doi:10.35541/cjd.20210389
Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology[J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475.doi:10.35541/cjd.20210389
| ［1］ | Rossetto O, Pirazzini M, Fabris F, et al. Botulinum neurotoxins: mechanism of action［J］. Handb Exp Pharmacol, 2021,263:35⁃47. doi: 10.1007/164_2020_355. |
| ［2］ | Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment［J］. Toxins （Basel）, 2019,11（9）:491. doi: 10. 3390/toxins11090491. |
| ［3］ | Kattimani V, Tiwari R, Gufran K, et al. Botulinum toxin application in facial esthetics and recent treatment indications （2013-2018）［J］. J Int Soc Prev Community Dent, 2019,9（2）:99⁃105. doi: 10.4103/jispcd.JISPCD_430_18. |
| ［4］ | Matak I, Bölcskei K, Bach⁃Rojecky L, et al. Mechanisms of botulinum toxin type A action on pain［J］. Toxins （Basel）, 2019,11（8）:459. doi: 10.3390/toxins11080459. |
| ［5］ | Ramachandran R, Marino MJ, Paul S, et al. A study and review of effects of botulinum toxins on mast cell dependent and independent pruritus［J］. Toxins （Basel）, 2018,10（4）:134. doi: 10.3390/toxins10040134. |
| ［6］ | List EK, Pascual JC, Zarchi K, et al. Mast cells in hidradenitis suppurativa: a clinicopathological study［J］. Arch Dermatol Res, 2019,311（4）:331⁃335. doi: 10.1007/s00403⁃019⁃01910⁃3. |
| ［7］ | Martina E, Diotallevi F, Radi G, et al. Therapeutic use of botulinum neurotoxins in dermatology: systematic review［J］. Toxins （Basel）, 2021, 13（2）:120. doi: 10.3390/toxins13020120. |
| ［8］ | 李健, 宋志强. 玫瑰痤疮面部潮红与红斑新认识［J］. 中华皮肤科杂志, 2021,54（4）:360⁃363. doi: 10.35541/cjd.20190920. |
| ［9］ | Scala J, Vojvodic A, Vojvodic P, et al. Botulin toxin use in rosacea and facial flushing treatment［J］. Open Access Maced J Med Sci, 2019,7（18）:2985⁃2987. doi: 10.3889/oamjms.2019. 784. |
| ［10］ | Bharti J, Sonthalia S, Jakhar D. Mesotherapy with Botulinum toxin for the treatment of refractory vascular and papulopustular rosacea［J］. J Am Acad Dermatol, 2018,19:S0190⁃9622（18）30808⁃30809. doi: 10.1016/j.jaad.2018.05.014. |
| ［11］ | Choi JE, Werbel T, Wang Z, et al. Botulinum toxin blocks mast cells and prevents rosacea like inflammation［J］. J Dermatol Sci, 2019,93（1）:58⁃64. doi: 10.1016/j.jdermsci.2018.12.004. |
| ［12］ | 刘乙萱, 姜沛彧, 刘韵祎, 等. 玫瑰痤疮神经源性炎症及肉毒毒素治疗相关机制的研究进展［J］. 中华皮肤科杂志, 2022,55（6）:552⁃554. doi: 10.35541/cjd.20200266. |
| ［13］ | Eshghi G, Khezrian L, Alirezaei P. Botulinum toxin A in treatment of facial flushing［J］. Acta Med Iran, 2016,54（7）:454⁃457. |
| ［14］ | Oh YJ, Lee NY, Suh DH, et al. A split⁃face study using botulinum toxin type B to decrease facial erythema index［J］. J Cosmet Laser Ther, 2011,13（5）:243⁃248. doi: 10.3109/14764172. 2011.613479. |
| ［15］ | Bloom BS, Payongayong L, Mourin A, et al. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea［J］. Dermatol Surg, 2015,41 Suppl 1:S9⁃S16. doi: 10.1097/DSS.000000000000 0277. |
| ［16］ | Dayan SH, Ashourian N, Cho K. A pilot, double⁃blind, placebo⁃controlled study to assess the efficacy and safety of incobotulinumtoxinA injections in the treatment of rosacea［J］. J Drugs Dermatol, 2017,16（6）:549⁃554. |
| ［17］ | Kim MJ, Kim JH, Cheon HI, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double⁃blind, placebo⁃controlled, split⁃face pilot study in rosacea patients with facial erythema［J］. Dermatol Surg, 2019,45（9）:1155⁃1162. doi: 10.1097/DSS.000000000000 1819. |
| ［18］ | Al⁃Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type⁃A in the treatment of rosacea⁃associated erythema and flushing［J］. Dermatol Ther, 2020,33（6）:e13976. doi: 10.1111/dth.13976. |
| ［19］ | Dhaliwal K, Griffin MF, Salinas S, et al. Optimisation of botulinum toxin type a treatment for the management of Raynaud′s phenomenon using a dorsal approach: a prospective case series［J］. Clin Rheumatol, 2019,38（12）:3669⁃3676. doi: 10.1007/s10067⁃019⁃04762⁃4. |
| ［20］ | Winter AR, Camargo Macias K, Kim S, et al. The effect of abobotulinum toxin A on the symptoms of Raynaud′s phenomenon: a case series［J］. Cureus, 2020,12（5）:e8235. doi: 10.7759/cureus.8235. |
| ［21］ | Quintana Castanedo L, Feito Rodríguez M, Nieto Rodríguez D, et al. Botulinum toxin A treatment for primary and secondary Raynaud′s phenomenon in teenagers［J］. Dermatol Surg, 2021,47（1）:61⁃64. doi: 10.1097/DSS.0000000000002397. |
| ［22］ | Zhou Y, Liu Y, Hao Y, et al. The mechanism of botulinum A on Raynaud syndrome［J］. Drug Des Devel Ther, 2018,12:1905⁃1915. doi: 10.2147/DDDT.S161113. |
| ［23］ | Jenkins SN, Neyman KM, Veledar E, et al. A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon［J］. J Am Acad Dermatol, 2013,69（5）:834⁃835. doi: 10.1016/j.jaad.2013.06.029. |
| ［24］ | Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma⁃associated Raynaud′s phenomenon: a randomized, double⁃blind, placebo⁃controlled clinical trial［J］. Arthritis Rheumatol, 2017,69（8）:1661⁃1669. doi: 10.1002/art.40123. |
| ［25］ | Motegi SI, Uehara A, Yamada K, et al. Efficacy of botulinum toxin B injection for Raynaud′s phenomenon and digital ulcers in patients with systemic sclerosis［J］. Acta Derm Venereol, 2017,97（7）:843⁃850. doi: 10.2340/00015555⁃2665. |
| ［26］ | 周末. A型肉毒毒素治疗系统性硬化症继发雷诺现象的疗效及皮肤镜评估［D］. 北京: 北京协和医学院中国医学科学院, 2017. doi: 10.7666/d.Y3277591. |
| ［27］ | Medina S, Gómez⁃Zubiaur A, Valdeolivas⁃Casillas N, et al. Botulinum toxin type A in the treatment of Raynaud′s phenomenon: a three⁃year follow⁃up study［J］. Eur J Rheumatol, 2018,5（4）:224⁃229. doi: 10.5152/eurjrheum.2018.18013. |
| ［28］ | Dhaliwal K, Griffin MF, Salinas S, et al. Optimisation of botulinum toxin type a treatment for the management of Raynaud′s phenomenon using a dorsal approach: a prospective case series［J］. Clin Rheumatol, 2019,38（12）:3669⁃3676. doi: 10.1007/s10067⁃019⁃04762⁃4. |
| ［29］ | Ennis D, Ahmad Z, Anderson MA, et al. Botulinum toxin in the management of primary and secondary Raynaud′s phenomenon［J］. Best Pract Res Clin Rheumatol, 2021,35（3）:101684. doi: 10.1016/j.berh.2021.101684. |
| ［30］ | Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain［J］. Toxins （Basel）, 2017,9（9）:260. doi: 10. 3390/toxins 9090260. |
| ［31］ | Xiao L, Mackey S, Hui H, et al. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia［J］. Pain Med, 2010,11（12）:1827⁃1833. doi: 10.1111/j.1526⁃4637. 2010.01003.x. |
| ［32］ | Apalla Z, Sotiriou E, Lallas A, et al. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double⁃blind, single⁃dose, placebo⁃controlled trial［J］. Clin J Pain, 2013,29（10）:857⁃864. doi: 10.1097/AJP.0b013e31827a72d2. |
| ［33］ | 原永康, 王红斌, 贾博, 等. 局部注射A型肉毒毒素治疗带状疱疹后遗神经痛的疗效观察［J］. 中华物理医学与康复杂志, 2015,37（9）:694⁃695. doi: 10.3760/cma.j.issn.0254⁃1424.2015. 09.014. |
| ［34］ | Ding XD, Zhong J, Liu YP, et al. Botulinum as a toxin for treating post⁃herpetic neuralgia［J］. Iran J Public Health, 2017,46（5）:608⁃611. |
| ［35］ | Hu Y, Zou L, Qi X, et al. Subcutaneous botulinum toxin⁃A injection for treating postherpetic neuralgia［J］. Dermatol Ther, 2020,33（1）:e13181. doi: 10.1111/dth.13181. |
| ［36］ | Li XL, Zeng X, Zeng S, et al. Botulinum toxin A treatment for post⁃herpetic neuralgia: a systematic review and meta⁃analysis［J］. Exp Ther Med, 2020,19（2）:1058⁃1064. doi: 10.3892/etm. 2019.8301. |
| ［37］ | Ayasse MT, Buddenkotte J, Alam M, et al. Role of neuroimmune circuits and pruritus in psoriasis［J］. Exp Dermatol, 2020,29（4）:414⁃426. doi: 10.1111/exd.14071. |
| ［38］ | Qin B, Sun C, Chen L, et al. The nerve injuries attenuate the persistence of psoriatic lesions［J］. J Dermatol Sci, 2021,102（2）:85⁃93. doi: 10.1016/j.jdermsci.2021.02.006. |
| ［39］ | Popescu MN, Beiu C, Iliescu MG, et al. Botulinum toxin use for modulating neuroimmune cutaneous activity in psoriasis［J］. Medicina （Kaunas）, 2022,58（6）:813. doi: 10.3390/medicina580 60813. |
| ［40］ | Zanchi M, Favot F, Bizzarini M, et al. Botulinum toxin type⁃A for the treatment of inverse psoriasis［J］. J Eur Acad Dermatol Venereol, 2008,22（4）:431⁃436. doi: 10.1111/j.1468⁃3083.2007. 02457.x. |
| ［41］ | Todberg T, Zachariae C, Bregnhøj A, et al. The effect of botulinum neurotoxin A in patients with plaque psoriasis ⁃ an exploratory trial［J］. J Eur Acad Dermatol Venereol, 2018,32（2）:e81⁃e82. doi: 10.1111/jdv.14536. |
| ［42］ | Aschenbeck KA, Hordinsky MK, Kennedy WR, et al. Neuromodulatory treatment of recalcitrant plaque psoriasis with onabotulinumtoxinA［J］. J Am Acad Dermatol, 2018,79（6）:1156⁃1159. doi: 10.1016/j.jaad.2018.07.058. |
| ［43］ | González C, Franco M, Londoño A, et al. Breaking paradigms in the treatment of psoriasis: Use of botulinum toxin for the treatment of plaque psoriasis［J］. Dermatol Ther, 2020,33（6）:e14319. doi: 10.1111/dth.14319. |
| ［44］ | Khattab FM, Samir MA. Botulinum toxin type⁃A versus 5⁃fluorouracil in the treatment of plaque psoriasis: Comparative study［J］. J Cosmet Dermatol, 2021,20（10）:3128⁃3132. doi: 10. 1111/jocd.14306. |
| ［45］ | Agamia NF, Sobhy N, Abd⁃Elraouf A, et al. Fractional CO2 laser for transcutaneous drug delivery of onabotulinum toxin in palmar hyperhidrosis［J］. Dermatol Surg, 2021,47（5）:678⁃683. doi: 10.1097/DSS.0000000000002901. |
| ［46］ | Wu CJ, Chang CK, Wang CY, et al. Efficacy and safety of botulinum toxin A in axillary bromhidrosis and associated histological changes in sweat glands: a prospective randomized double⁃blind side⁃by⁃side comparison clinical study［J］. Dermatol Surg, 2019,45（12）:1605⁃1609. doi: 10.1097/ DSS.000 0000000001906. |
| ［47］ | Qiao Z, Yang H, Jin L, et al. The efficacy and safety of botulinum toxin injections in preventing postoperative scars and improving scar quality: a systematic review and meta⁃analysis［J］. Aesthetic Plast Surg, 2021,45（5）:2350⁃2362. doi: 10.1007/s00266⁃021⁃02196⁃5. |
| ［48］ | Sun P, Lu X, Zhang H, et al. The efficacy of drug injection in the treatment of pathological scar: a network meta⁃analysis［J］. Aesthetic Plast Surg, 2021,45（2）:791⁃805. doi: 10.1007/s00266⁃019⁃01570⁃8. |
| ［49］ | Grimstad Ø, Kvammen BØ, Swartling C. Botulinum toxin type B for hidradenitis suppurativa: a randomised, double⁃blind, placebo⁃controlled pilot study［J］. Am J Clin Dermatol, 2020,21（5）:741⁃748. doi: 10.1007/s40257⁃020⁃00537⁃9. |
| ［50］ | Vachiramon V, Kositkuljorn C, Leerunyakul K, et al. A study of botulinum toxin A for ultraviolet⁃induced hyperpigmentation: a randomized controlled trial［J］. Dermatol Surg, 2021,47（5）:e174⁃e178. doi: 10.1097/DSS.0000000000002943. |
| ［51］ | Sayed KS, Hegazy R, Gawdat HI, et al. The efficacy of intradermal injections of botulinum toxin in the management of enlarged facial pores and seborrhea: a split face⁃controlled study［J］. J Dermatolog Treat, 2021,32（7）:771⁃777. doi: 10.1080/09546634.2019.1708241. |
| ［52］ | Shirshakova M, Morozova E, Sokolova D, et al. The effectiveness of botulinum toxin type A （BTX⁃A） in the treatment of facial skin oily seborrhea, enlarged pores, and symptom complex of post⁃acne［J］. Int J Dermatol, 2021,60（10）:1232⁃1241. doi: 10.1111/ijd.15574. |
| ［53］ | Zhang L, Yu Q, Wang Y, et al. A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients［J］. Dermatol Ther, 2019,32（4）:e12785. doi: 10.1111/dth.12785. |
| ［54］ | Zhou Y, Yu S, Zhao J, et al. Effectiveness and safety of botulinum toxin type A in the treatment of androgenetic alopecia［J］. Biomed Res Int, 2020,2020:1501893. doi: 10.1155/2020/1501893. |
| ［55］ | Zhang H, Tang K, Wang Y, et al. Botulinum toxin in treating Hailey⁃Hailey disease: a systematic review［J］. J Cosmet Dermatol, 2021,20（5）:1396⁃1402. doi: 10.1111/jocd.13963. |
| ［56］ | Rodríguez⁃Villa Lario A, Vega⁃Díez D, González⁃Cañete M, et al. Aquagenic keratoderma with dorsal involvement treated with botulinum toxin. Case report and review of literature［J］. Dermatol Ther, 2020,33（6）:e14347. doi: 10.1111/dth.14347. |
| ［57］ | Wen X, Li Y, Hamblin MR, et al. Facial manifestations of pachydermoperiostosis treated with botulinum toxin type⁃A: report of 3 cases［J］. Acta Derm Venereol, 2017,97（6）:761⁃762. doi: 10.2340/00015555⁃2645. |
| ［58］ | Lu Y, Qi X, Zhou X, et al. Intralesional botulinum toxin A injection for treating nodular scabies［J］. Dermatol Ther, 2020,33（6）:e14163. doi: 10.1111/dth.14163. |
| ［59］ | Turkmani MG, Alnomair N. Enhancement of the aesthetic outcome of scleroderma en coup de sabre with botulinum toxin injection［J］. JAAD Case Rep, 2018,4（6）:579⁃581. doi: 10. 1016/j.jdcr.2018.03.023. |
| ［60］ | Koren A, Sprecher E, Reider E, et al. A treatment protocol for botulinum toxin injections in the treatment of pachyonychia congenita⁃associated keratoderma［J］. Br J Dermatol, 2020,182（3）:671⁃677. doi: 10.1111/bjd.18169. |
| ［61］ | Zhong J, Lan Y, Fu S, et al. Botulinum toxin A injection for treatment of chronic skin ulcer: a case series and literature review［J］. Int J Low Extrem Wounds, 2019,18（1）:97⁃103. doi: 10.1177/1534734618816589. |
| [1] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. 遗传性血管性水肿诊疗路径皮肤科专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(6): 497-502. |
| [2] | 于金蕾 吴桥芳 孙悦鑫 包军 周映. 佩索利单抗治疗6例泛发性脓疱型银屑病临床观察[J]. 中华皮肤科杂志, 2025, 0(5): 20240440-e20240440. |
| [3] | 中华医学会皮肤性病学分会银屑病学组. [开放获取] 阿普米司特治疗银屑病专家指导意见（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 416-424. |
| [4] | 李紫钰 鲁严. 关注新型冠状病毒感染后重症皮肤病[J]. 中华皮肤科杂志, 2025, 58(4): 378-383. |
| [5] | 吕铭悦 满孝勇. 细胞治疗在系统性红斑狼疮中的应用[J]. 中华皮肤科杂志, 2025, 58(4): 374-377. |
| [6] | 中国医师协会皮肤科医师分会儿童学组 中华医学会皮肤性病学分会银屑病学组. 【开放获取】 儿童脓疱型银屑病诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 297-306. |
| [7] | 何春霞 晋红中. 【开放获取】 急危重皮肤病的诊疗原则、现状、挑战和展望[J]. 中华皮肤科杂志, 2025, 58(4): 307-314. |
| [8] | 木葵 郭慧 文海泉 龙海 刘昱 罗帅寒天 黄馨 周星雨 肖嵘 李亚萍. 基于标准治疗联合泰它西普治疗25例系统性红斑狼疮的疗效和安全性分析[J]. 中华皮肤科杂志, 2025, 58(4): 322-327. |
| [9] | 王文秋 李承新 王睿. 生物制剂治疗银屑病复发的研究现状[J]. 中华皮肤科杂志, 2025, 0(3): 20230301-e20230301. |
| [10] | 李秀珍 徐秀莲. 白细胞介素23抑制剂治疗对银屑病共病的影响[J]. 中华皮肤科杂志, 2025, 58(3): 268-272. |
| [11] | 陈良宏 孙艳 王敬玉 吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 266-268. |
| [12] | 薛珂 陈佳 李斌. 系统性红斑狼疮靶向治疗研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240530-e20240530. |
| [13] | 罗帅寒天 龙海 陆前进. 2024年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240689-e20240689. |
| [14] | 许焯红 胡煜 顾恒. 间充质干细胞来源的外泌体在皮肤病中的作用[J]. 中华皮肤科杂志, 2025, 0(3): 20220881-e20220881. |
| [15] | 张笑旭 罗素菊. 乌帕替尼治疗6例掌跖脓疱病的临床疗效与安全性分析[J]. 中华皮肤科杂志, 2025, 0(2): 20230772-e20230772. |
|
